Novo Looking To Position Liraglutide As First Once-Daily Injection Following Oral Drug Failures
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk reports positive top-line data from the first of five Phase III studies evaluating the GLP-1 analog.